Skip to main content

Table 1 Elite Controller Study Population Characteristics.

From: T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers

Subject ID

Gender1

Age2

CD43

CD83

Duration of infection2

%CD38+DR+CD8+

Duration CD4 FUP/VL control2,3

#CD4 assessments

Annual Rate of CD4 decline4

EC 1

M

37

680

680

1

14.60

2.91

8

9.4 (-55.9,74.8)

EC 2

M

31

715

384

5

5.42

5.14

11

-17.7 (-56.2,20.8)

EC 3

M

68

660

1082

4

3.59

5.16

17

6.19 (-14.5,26.7)

EC 4

F

58

714

714

4

4.68

5.77

14

-6.73 (-50.7,37.2)

EC 5

M

53

310

730

6

3.95

5.27

14

-52.6 (-76.6,28.5)

EC 6

F

46

720

631

11

6.63

8.75

25

-7.4 (-22.7,8.0)

EC 7

M

37

1040

1095

11

4.33

9.64

22

14.4 (-6.5,35.3)

EC 8

F

40

737

303

12

7.11

12.08/14.52

22

-44.2 (-58.0,-30,4)

EC 9

M

53

800

288

10

7.35

14.88

35

15.9 (10.3,21.6)

EC 10

M

45

1050

1296

20

7.41

12.27

22

-11.2 (-27.9,5.4)

EC 11

M

39

689

455

9

10.20

16.78/9.12

86

-48.9 (-59.2,-38.6)

EC 12

F

33

728

434

10

2.36

17.30

79

-49.2 (-53.4,-45.0)

EC 13

M

47

770

1130

19

12.70

20.02/21.63

17

-33.0 (-50.6,-15.3)

EC 14

M

31

928

1566

2

20.00

2.75

N.A.

N.A.5

EC 15

F

31

442

816

2

12.40

4.75

4

15.8 (-19.3,50.9)

EC 16

F

60

800

1026

13

3.00

13.64

8

-5.3 (-58,7,58.0)

EC 17

M

40

460

307

4

6.35

3.87

10

4.3 (-40.9,49.6)

EC 18

M

42

870

551

1

8.27

1.50

N.A.

N.A.

EC 19

F

30

692

627

6

10.10

2.17

6

-17.0 (-121.5,87.5)

EC 20

F

40

576

498

12

20.20

15.18/15.73

13

-30.9 (-50.2,-11.7)

EC 21

M

36

343

804

14

12.20

1.05

N.A.

N.A.

EC 22

M

61

670

540

4

12.5

4.62

11

32.1 (-27.3,91.5)

EC 23

M

53

740

820

11

33.2

18.01

16

-15.1 (-33.3,3.0)

EC 24

M

41

978

787

1

37.3

11.24

29

-16.0 (-27.6,-4.4)

EC 25

M

55

990

680

10

15.3

9.48

16

-29.0 (-70.5, 12.5)

EC 26

M

68

970

400

17

17.5

13.18

19

14.5 (3.8,25.2)

EC 27

M

41

1200

860

11

13.9

12.39

34

28.6 (7.4,49.7)

EC 28

M

48

700

920

8

35.4

17.20

35

-1.4 (-5.0,2.1)

EC 29

F

53

499

202

8

28.9

N.A.

N.A.

N.A.

EC 30

M

40

510

1286

14

21.5

N.A.

N.A.

N.A.

EC 31

F

47

485

277

20

17.3

N.A.

N.A.

N.A.

EC 32

F

56

865

388

15

20.7

N.A.

N.A.

N.A.

EC 33

F

56

1488

1012

17

2.39

N.A.

N.A.

N.A.

EC 34

M

56

801

713

18

20.7

N.A.

N.A.

N.A.

  1. 1M = male;F = female
  2. 2 years.
  3. 3The duration of CD4 follow up/duration of viral load control if different from duration of CD4 follow up.
  4. 4 cells/mm3 (95% confidence intervals).
  5. 5 Not available (insufficient information available to calculate a slope of CD4 counts change).